Insmed has closed a public offering of common stock that generated net proceeds of ~$377.7 million, the company said. The proceeds will be used in large part for continued development, regulatory submissions, and potential commercialization of ALIS amicakin liposome inhalation suspension. According to the announcement, planned uses for the proceeds include "invest … [Read more...] about Insmed public offering nets over $377 million
Business
Pulmatrix licenses PUR0200 dry powder tiotropium to Vectura
Pulmatrix has announced a licensing agreement with Vectura for US development of Pulmatrix's PUR0200 dry powder tiotropium formulation for the treatment of COPD. Vectura will pay Pulmatrix a $1 million "technology access fee" on achievement of certain milestones and will take responsibility for US development beginning immediately. According its own announcement, … [Read more...] about Pulmatrix licenses PUR0200 dry powder tiotropium to Vectura
Pulmatrix gets development award from Cystic Fibrosis Foundation Therapeutics for PUR1900
According to Pulmatrix, the Cystic Fibrosis Foundation Therapeutics (CFFT) will provide funds to support non-clinical development of PUR1900, an itraconazole DPI, for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis and asthma patients. The amount of the award was not specified by Pulmatrix; however, the CFFT website says that … [Read more...] about Pulmatrix gets development award from Cystic Fibrosis Foundation Therapeutics for PUR1900
Ascend Therapeutics now promoting Egalet’s Sprix nasal spray in the US
Ascend Therapeutics is now promoting Egalet's Sprix ketorolac tromethamine nasal spray for the treatment of moderate-to-moderately severe pain to women's healthcare providers in the US, Egalet said. According to Egalet, the companies signed the agreement allowing Ascend to promote the product in July 2017. Egalet Chief Commercial Officer Patrick Shea commented, … [Read more...] about Ascend Therapeutics now promoting Egalet’s Sprix nasal spray in the US
Dance Biopharm buys back Asia license for Dance-501 inhaled insulin
Dance Biopharm announced that it has bought back the Asia license for its Dance-501 soft mist inhaled insulin by purchasing the license holder, Harmony Biopharm Limited, from Harmony Plus Holdings Limited (Harmony). Dance said that Harmony will receive stock and a percentage of future sales of the product in China and that Harmony will continue to advise Dance on … [Read more...] about Dance Biopharm buys back Asia license for Dance-501 inhaled insulin
CF PharmTech raises $65 million for inhaled drug development
Chinese inhaled drug developer and CDMO CF PharmTech has raised $65M in a Series D financing round led by Future Industry Investment Fund (managed by SDIC Fund Management), the company said. The money is to be used for development of the company's own OINDPs and for expansion of its CDMO services. SDIC Fund Management Managing Direct Hai Lu said, "Drug delivery via … [Read more...] about CF PharmTech raises $65 million for inhaled drug development
Lee’s Pharmaceutical to acquire controlling interest in Windtree Therapeutics
Hong Kong-based Lee's Pharmaceutical will advance Windtree Therapeutics up to $3.9 million through the end of October 2017 during negotiations for Lee's to acquire a controlling interest in Windtree. The first installment of the loan has already been received by Windtree, the company said. In June 2017, Windtree announced that Lee's had acquired the rights to … [Read more...] about Lee’s Pharmaceutical to acquire controlling interest in Windtree Therapeutics
Adherium announces sale of 100,000th Smartinhaler
Adherium has now manufactured and sold 100,000 of its Smartinhaler inhaler monitoring devices, the company has announced. According to Adherium, the Smartinhaler has been sold in more than 40 countries to date. The Smartinhaler platform received FDA 510(k) clearance in 2014 and is currently being used in the myAirCoach project in Europe. In 2015, Adherium … [Read more...] about Adherium announces sale of 100,000th Smartinhaler
Aradigm gets SBIR grant for development of Linhaliq and Lipoquin for NTM
Aradigm Corporation has received a 2-year Small Business Initiative Research (SBIR) grant of about $972,000 from the National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH) for development of Linhaliq and Lipoquin to treat pulmonary non-tuberculous mycobacteria (NTM) infections, the company said. The grant will support … [Read more...] about Aradigm gets SBIR grant for development of Linhaliq and Lipoquin for NTM
Verona Pharma developing MDI and DPI formulations of RPL554
According to Verona Pharma's mid-year update, the company is developing MDI and DPI formulations of its RPL554, an inhaled PDE3/PDE4 inhibitor. Nebulized RPL554 is currently in Phase 2 development, and Verona reported positive results from a Phase 2a trial of RPL554 for the treatment of acute exacerbations in COPD patients in March 2016. The company said that it … [Read more...] about Verona Pharma developing MDI and DPI formulations of RPL554